⚠︎ Risk warning: leveraged derivatives on unregulated platforms — you can lose everything you deposit. Not investment advice.
Hyperliquid vs ApeX (2026): Verifiable L1 vs ApeX Omni on zkLink
Facts verified against each venue's official docs on 2026-09-24. Any comparison of volume or liquidity reflects a point-in-time reading that moves constantly — treat it as a reading, not a fixed ranking.
One quick clarification first, because the name is overloaded: the older "ApeX Pro" that ran on StarkEx was discontinued in April 2025. The live product is ApeX Omni, which settles on zkLink Nova — a layer-3 Validium — with order matching handled off-chain; our ApeX Omni review covers it in full. It's a large venue: 88 crypto perps and 39 TradFi perps on its symbols API on 2026-09-24, the latter covering stocks, indexes and commodities such as gold alongside crypto. Hyperliquid is the opposite bet: fewer bells, but a fully on-chain order book on its own L1 that anyone can verify. The most important difference between them, though, isn't markets or fees — it's how much you can trust the venue's custody, so we'll get to that directly.
Note on jurisdiction: both venues restrict US persons. Hyperliquid blocks US users; ApeX Omni requires no identity check (no KYC), but its Terms of Use explicitly prohibit US persons and sanctioned jurisdictions and ban VPN circumvention — so "no KYC" is not the same as "available everywhere." Check each venue's own terms before signing up.
Verdict
Breadth vs custody safety. ApeX Omni is a large venue — 127 perps on its API, including stock, index and commodity contracts — with competitive fees; but it settles on zkLink Nova, which L2BEAT flags CRITICAL (contracts upgradeable by a single key, no exit window). Hyperliquid trades breadth for a fully on-chain, verifiable book and a published audit. Pick ApeX for market breadth if you accept the documented custody-upgrade risk; pick Hyperliquid for verifiability and safer-by-design custody.
At a glance
| Hyperliquid | ApeX | |
|---|---|---|
| Architecture | On-chain OB · own L1 | Off-chain matching · zkLink Nova |
| Markets | Broad crypto set | 88 crypto + 39 TradFi perps (API) WINNER |
| Fees (perps) | 0.045% / 0.015% t/m | 0.050→0.025% / 0.020→0% t/m |
| Funding | Hourly · P2P | Hourly · ±0.05% cap (docs) |
| Max leverage | Up to 40x | Up to 100x (BTC, ETH) |
| Custody risk | Own L1 · Zellic-audited legacy bridge WINNER | zkLink Nova: L2BEAT CRITICAL |
| Token | HYPE (live) | APEX (live) |
facts verified · each venue's docs
What you can trade, and the fees
ApeX Omni's headline strength is breadth: its symbols API returned 88 tradable crypto perps and 39 TradFi perps on 2026-09-24 (CoinGecko counts 350 pairs across all its products), and unlike Hyperliquid it lists stock, index and commodity perps — Apple, an S&P 500 tracker, gold — next to crypto, each family in its own cross-margined account. Hyperliquid is crypto-native and doesn't offer traditional-asset products directly (its RWA exposure comes through HIP-3 builder markets on the same book — see our HIP-3 explainer).
On cost, ApeX's tiered schedule is competitive: 0.050% taker / 0.020% maker at Level 1, improving to 0.025% / 0.000% at Level 7, with levels set daily by 14-day volume or by APEX and esAPEX staked (effective 1 October 2025 per its fee page — see our ApeX fees breakdown), and funding settled hourly and capped at ±0.05% per hour. Hyperliquid runs 0.045% taker / 0.015% maker, cut by volume tiers and HYPE staking — see our full breakdown. On the base taker fee the two are close; ApeX reaches a lower floor at very high volume. ApeX also allows higher headline leverage — up to 100x on majors versus Hyperliquid's ~40x — which is more capital efficiency and a faster liquidation, in equal measure.
The custody question (read this before the fees decide it)
This is where the two genuinely diverge, and it's the most decision-relevant fact on the page. Hyperliquid runs its own L1 with a fully on-chain, verifiable order book and a published Zellic audit of its legacy bridge. ApeX Omni settles on zkLink Nova, and the independent L2 risk tracker L2BEAT flags that chain with several CRITICAL findings: it "includes unverified contracts," its "critical contracts can be upgraded by an EOA which could result in the loss of all funds," and there is no exit window — upgrades can take effect instantly, with no delay for a user to withdraw first. In plain terms: a single key can, per L2BEAT, change the contracts holding user funds with no warning. This is the same class of risk we flagged on edgeX — arguably starker here, since edgeX at least had a short exit window — though it stems from ApeX's current zkLink infrastructure, not shared contracts with edgeX. ApeX is self-custodial in that your keys stay in your wallet, but the contracts your funds settle through carry this documented upgrade risk. Weigh it before size.
Where ApeX wins
- Far broader markets, including stock, index and commodity perps alongside crypto — Hyperliquid has no direct equivalent.
- A competitive tiered fee schedule that reaches zero maker / 0.025% taker at the top, and no identity KYC to start.
- A mid-table venue by size: ninth by open interest ($154m) on DefiLlama's derivatives ranking on 2026-09-24, with $32b of reported 30-day volume.
- Up to 100x leverage on BTC and ETH for traders who specifically want it.
Where Hyperliquid wins
- The custody story. A fully on-chain, verifiable order book and a published audit, versus a settlement chain L2BEAT flags for CRITICAL, no-exit-window, EOA-upgradeable contract risk.
- Order matching you can inspect on-chain, rather than an off-chain matching engine you trust.
- A clearer operating structure. Hyperliquid runs its own L1; ApeX's own documents are inconsistent about its entity — its Terms (last updated 27 July 2026) name "APEX DAO Inc." under Panama governing law and say it "does not deploy APEX Software for public use", while its CoinGecko listing cites incorporation in Saint Vincent and the Grenadines.
- Lower headline leverage (~40x) is arguably safer than 100x, which liquidates on a small move.
Which to pick
If you want one venue to trade crypto and stocks or gold as perps, with a deep market list and competitive fees, ApeX Omni offers that — provided you've read the custody section above and are comfortable with a settlement chain that carries a documented, CRITICAL upgrade risk. If the venue's custody and verifiability matter more to you than market breadth — a book you can audit on-chain, a published security audit, and a clearer operating structure — Hyperliquid is the safer-by-design choice. Read our full Hyperliquid review, and weigh both against the field in our perp DEX rankings before committing capital.
Related comparisons
Venue reviews: Hyperliquid review · ApeX review
FAQ
Can I really trade stocks on ApeX?
Yes — as perpetuals, not as real shares. ApeX Omni lists stock, index and commodity perps (e.g. AAPL, SPY, gold) alongside crypto, in a separate TradFi account. They're synthetic, Chainlink-priced instruments settled in USDT, not regulated brokerage positions, closed on weekends and US public holidays, and can diverge from the underlying — especially while the real market is shut.
Is ApeX safe to use?
No exploit of ApeX itself turned up in our checks, but "no incident found" is not a clean bill of health — and the more important point is the documented one: L2BEAT flags ApeX Omni's settlement chain (zkLink Nova) with CRITICAL risks, including contracts upgradeable by a single key with no exit window. That's a structural custody risk to weigh, independent of whether a hack has happened. See our risk disclosure.
Does ApeX require KYC?
No identity verification is required to trade — it's wallet-connect only. But its Terms of Use still contractually prohibit US persons and sanctioned jurisdictions and forbid using a VPN to get around that, so no-KYC does not mean it's open to everyone.
Perpetual futures carry substantial risk regardless of venue — see our risk disclosure before trading either exchange.
the Hyperliquid link is an affiliate link — we may earn a commission at no extra cost to you; no commercial relationship with ApeX · methodology